- Home
- TPCS vs EXEL Comparison
TPCS vs EXEL Comparison
Compare TPCS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPCS
- EXEL
- Stock Information
- Founded
- TPCS 1956
- EXEL 1994
- Country
- TPCS United States
- EXEL United States
- Employees
- TPCS N/A
- EXEL N/A
- Industry
- TPCS Metal Fabrications
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TPCS Industrials
- EXEL Health Care
- Exchange
- TPCS Nasdaq
- EXEL Nasdaq
- Market Cap
- TPCS 51.4M
- EXEL 10.4B
- IPO Year
- TPCS N/A
- EXEL 2000
- Fundamental
- Price
- TPCS $5.50
- EXEL $39.14
- Analyst Decision
- TPCS
- EXEL Buy
- Analyst Count
- TPCS 0
- EXEL 21
- Target Price
- TPCS N/A
- EXEL $43.65
- AVG Volume (30 Days)
- TPCS 60.2K
- EXEL 2.2M
- Earning Date
- TPCS 08-21-2025
- EXEL 10-28-2025
- Dividend Yield
- TPCS N/A
- EXEL N/A
- EPS Growth
- TPCS N/A
- EXEL 81.76
- EPS
- TPCS N/A
- EXEL 2.08
- Revenue
- TPCS $33,424,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- TPCS N/A
- EXEL $9.24
- Revenue Next Year
- TPCS N/A
- EXEL $13.04
- P/E Ratio
- TPCS N/A
- EXEL $18.75
- Revenue Growth
- TPCS 3.78
- EXEL 10.73
- 52 Week Low
- TPCS $2.05
- EXEL $25.17
- 52 Week High
- TPCS $6.25
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- TPCS 56.91
- EXEL 54.38
- Support Level
- TPCS $5.26
- EXEL $38.37
- Resistance Level
- TPCS $5.50
- EXEL $39.27
- Average True Range (ATR)
- TPCS 0.28
- EXEL 0.98
- MACD
- TPCS -0.04
- EXEL 0.31
- Stochastic Oscillator
- TPCS 57.89
- EXEL 87.13
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.